ARK Genomic Revolution ETF (BATS:ARKG) Shares Sold by Valley National Advisers Inc.

Valley National Advisers Inc. lowered its position in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 39.6% in the first quarter, HoldingsChannel.com reports. The firm owned 1,089 shares of the company’s stock after selling 715 shares during the quarter. Valley National Advisers Inc.’s holdings in ARK Genomic Revolution ETF were worth $31,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Principal Securities Inc. purchased a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at $32,000. Northwest Financial Advisors purchased a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at $47,000. Tidemark LLC purchased a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at $48,000. Naples Money Management LLC purchased a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at $63,000. Finally, ICA Group Wealth Management LLC purchased a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at $66,000.

ARK Genomic Revolution ETF Price Performance

ARKG traded up $0.27 on Wednesday, reaching $23.16. The company had a trading volume of 1,341,867 shares. The stock’s 50-day simple moving average is $24.96 and its 200-day simple moving average is $27.93.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.